Company: BFRG
Filing Date: 2025-03-14
Form Type: 10-K
Source: 0001493152-25-010367
Chunk: 571

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-03-14
Form: 10-K
Item: Item 5
Chunk 571
---
 on current expectations
and assumptions that are subject to risk, uncertainties, and other factors. These statements are often identified by the use of words
such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,”
“could,” “estimate,” or “continue,” and similar expressions or variations. Actual results could differ
materially because of the factors discussed in “Risk Factors” elsewhere in this Annual Report on Form 10-K, and other factors
that we may not know.

 24 

OVERVIEW

Bullfrog
AI Holdings, Inc. was incorporated in the State of Nevada on February 6, 2020. Bullfrog AI Holdings, Inc. is the parent company of Bullfrog
AI, Inc. and Bullfrog AI Management, LLC, which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. Operations
are currently conducted through Bullfrog AI Holdings, Inc., which began operations on February 6, 2020. We are a company focused specifically
on advanced Artificial Intelligence / Machine Learning (“AI/ML”) analysis of complex data in the advancement of medicine.
Our AI/ML platform (trade name: bfLEAP™) was created from technology originally developed at The Johns Hopkins University Applied
Physics Laboratory (“JHU-APL”). Subsequently, we have developed new tools and capabilities composed of an ensemble of machine
learning and artificial intelligence models.

In
February 2018, the Company secured an original exclusive, worldwide, royalty-bearing license from JHU-APL for the technology underlying
our bfLEAP™ platform. The license covers three (3) issued patents, one (1) new provisional patent application, non-patent rights
to proprietary libraries of algorithms and other trade secrets including modifications and improvements. We entered into a license agreement
in July 2022 that provides the Company with new intellectual property and also encompasses most of the intellectual property from the
February 2018 license. Our objective is to utilize bfLEAP™, our AI/ML platform, with a precision medicine approach toward drug
development with biopharmaceutical collaborators, as well as our own internal clinical development programs. We believe the bfLEAP™
platform is ideally suited for evaluating pre-clinical and clinical trial data generated in translational research and clinical trial
settings in order to lead to faster, less expensive drug approvals.

Our
aim is to improve the odds of success in each stage of